The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study

Table 5

Number of new cases, population at risk, estimated hazard ratios (HR), and 95% confidence intervals (CI) for endometrial cancer estimated using the multivariate Cox’s regression model from the National Health Insurance Catastrophic Illnesses Registry of Taiwan for all tamoxifen-treated breast cancer women 55–79 years old and followed up from 1998 to 2008.

Presence of endometrial cancer during the follow-up period	TMX users using Chinese medicine containing ginseng. Number of cases/person-years	TMX users not using Chinese medicine. Number cases/person-years	TMX users using Chinese medicine containing ginseng divided by TMX users not using Chinese medicine. Adjusted HR^* (95% CI)
Total TMX users	30/25,206	47/27,681	0.75 (0.47–1.19)
Duration of TMX treatment
<2 years	10/10,379	33/15,576	0.50 (0.24–1.01)
2–4 years	12/7,396	11/6,370	0.93 (0.40–2.14)
>4 years	8/7,431	3/5,736	1.97 (0.51–7.66)
Cumulative TMX doses
<7,500 mg	7/6,293	26/10,695	0.51 (0.22–1.17)
7,500–14,999 mg	4/4,051	7/4,868	0.55 (0.16–1.91)
15,000–29,999 mg	10/7,335	11/6,270	0.77 (0.32–1.84)
≥30,000 mg	9/7,527	3/5,848	2.44 (0.64–9.31)

Adjusted for age at breast cancer diagnosis, insured salary, insured region, diabetes and hypertension, duration of TMX treatment, and cumulative TMX doses.
TMX refers to tamoxifen.